Sotera Health operates in the Life Science Tools & CDMO theme, providing outsourced services to healthcare and life-science customers. The company sits in Services-Misc Health & Allied Services and is listed on NasdaqGS with a market capitalization near $5.23 billion as of the pick date.
Revenue has been positive year-over-year each reported quarter and reached $321.4 million in CY2026Q2, a roughly 9.2% gain versus the year-ago quarter. Quarterly revenue has ranged from about $248.2 million to $321.4 million over the sample, showing steady top-line gains but not an accelerating revenue trend. GAAP diluted EPS has moved from a loss of $0.05 in CY2023Q3 to earnings of $0.19 in CY2026Q2, with EPS acceleration flagged in the fundamentals.
The case for leadership rests on improving profitability, visible institutional support and a constructive technical trend. Quarterly GAAP EPS expansion — including the recent $0.19 print and multiple quarters of double-digit EPS growth in the leader-selection pass list — aligns with demand for outsourced life-science services, while 409 reporting institutions and a high institutional score indicate broad ownership interest.
Why now
Timing is driven by the latest quarter (CY2026Q2) where revenue reached $321.4 million and GAAP diluted EPS rose to $0.19, by an established technical uptrend, and by institutional positioning reported as of 2026-06-30; those factors together make the company more visible to growth and thematic investors now.
The setup
The price sits near $18.33, slightly below the 50-day average ($18.38) and the 9/21-day EMAs (both $18.82), while comfortably above the 200-day SMA ($16.84). Weinstein stage is Stage 2 — continuation — with six of seven trend checks passed; the only failed check is the 150-day MA above the 200-day MA. Entry readiness is labeled watch, not actionable, reflecting no fresh breakout and the price about 2.6% below the short EMAs. Relative strength has outperformed SPY over three and six months but lagged over 12 months.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (9 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $0.98 (+14%) · FY'27E $1.07 (+9%) — 9 analysts
Risks
Revenue growth is steady but not accelerating, which limits upside if customers pull back or pricing weakens. GAAP EPS has been volatile, including quarters with losses, so earnings can swing and affect sentiment. Technically, the stock is in a continuation phase without a fresh breakout, so a loss of trend or broader market weakness could reverse the recent gains.
Framework fit
CANSLIM
7/7- CCurrent quarterly GAAP EPS growth ≥ 25%+533%✓
- AAnnual GAAP EPS growth ≥ 25%+69%✓
- NNew highs — within 15% of 52-week high-6.34%✓
- SSupply/demand — up-day volume leads1.03x✓
- LLeader — outperforming the S&P 500+18% 6m✓
- IInstitutional sponsorshipmodel score 9/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
6/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price is above a rising 30-week proxy, with the 200-day line used as a separate confirmation.